Boardroom Alpha
Start trial
Boardroom Alpha
MLTX · Additional Proxy Materials (DEFA14A) · Filed April 21, 2026

Moonlake Immunotherapeutics — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 21, 2026
Ticker
MLTX
Accession
0001140361-26-015917
Moonlake Immunotherapeutics on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

MoonLake Immunotherapeutics' annual meeting includes Spike Loy's election and standard governance votes; the Board urges voting For all items.

About Moonlake Immunotherapeutics
Market cap
$1.3B
1Y TSR
−60.5%
3Y TSR
−18.1%
Board grade
B
Sector
Healthcare
CEO
Jorge Santos da Silva
Last annual meeting: Jun 4, 2026 · View full Moonlake Immunotherapeutics profile →
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.  )
 
 
 
 
Filed by the Registrant
 
 
☒
Filed by a Party other than the Registrant
 
 
 ☐
 
 
 
 
Check the appropriate box:
 ☐
Preliminary Proxy Statement
 ☐
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐
Definitive Proxy Statement
 ☒
Definitive Additional Materials
 ☐
Soliciting Material under §240.14a-12
 
MoonLake Immunotherapeutics
 
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
 
Payment of Filing Fee (Check all boxes that apply):
☒
No fee required.
 ☐
Fee paid previously with preliminary materials.
 ☐
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 Your Vote Counts!  *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V90809-P50459  MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29  ZUG, SWITZERLAND 6300  MOONLAKE IMMUNOTHERAPEUTICS  2026 Annual General Meeting of Shareholders  Vote by June 3, 2026  11:59 PM ET  You invested in MOONLAKE IMMUNOTHERAPEUTICS and it’s time to vote!  You have the right to vote on proposals being presented at the Annual General Meeting of Shareholders. This is an important notice  regarding the availability of proxy materials for the shareholder meeting to be held on June 4, 2026.  Get informed before you vote  View the Notice, Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by  requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote in Person at the Meeting*  June 4, 2026  8:00 a.m. Eastern Time  At the offices of Gibson, Dunn & Crutcher LLP Located at 200 Park Avenue  New York, New York 10166 
 
 Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials at www.ProxyVote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting.  Please follow the instructions on the reverse side to vote on these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  V90810-P50459  1. Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified.  For  Nominee:  1a. Spike Loy  2. Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.  For  3. Approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.  For  4. Approval of an amendment and restatement of the Company’s 2022 Equity Incentive Plan.  For  NOTE: Such other business as may properly come before the meeting or any adjournments or postponements thereof.  Voting Items  Board Recommends 
 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting ForecastSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Moonlake Immunotherapeutics (MLTX)

Continue researching
Reference

Frequently asked questions

When did Moonlake Immunotherapeutics file this DEFA14A?
Moonlake Immunotherapeutics (MLTX) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 21, 2026. The accession number assigned by EDGAR is 0001140361-26-015917.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
MoonLake Immunotherapeutics' annual meeting includes Spike Loy's election and standard governance votes; the Board urges voting For all items. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Moonlake Immunotherapeutics's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Moonlake Immunotherapeutics has filed under CIK 1821586, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer